VB vs XBI
Vanguard Small-Cap ETF vs SPDR S&P Biotech ETF
- • VB has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VB pays a higher dividend yield (1.19%).
Side-by-side metrics
| Metric | VB | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.19% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $188.57B | $10.73B |
YTD return | 15.20% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.10 | 1.10 |
P/E ratio | 21.93 | — |
Last price | $299.86 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
VB top holdings
| FLEX | Flex Ltd | 0.69% |
| ALAB | Astera Labs Inc | 0.62% |
| CIEN | Ciena Corp | 0.51% |
| RKLB | Rocket Lab Corp | 0.51% |
| CRDO | Credo Technology Group Holding Ltd | 0.48% |
| BE | Bloom Energy Corp Class A | 0.47% |
| EME | EMCOR Group Inc | 0.46% |
| JBL | Jabil Inc | 0.45% |
| COHR | Coherent Corp | 0.42% |
| FIX | Comfort Systems USA Inc | 0.40% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About VB
VB (Vanguard Small-Cap ETF) is US small-cap stocks across sectors. Managed by Vanguard, the fund carries $188.6B in assets under management, an expense ratio of 0.03%, a dividend yield of 1.19%. Its largest holding is Flex Ltd (FLEX), which represents 0.7% of the portfolio. Real Estate is the fund's largest sector exposure at 7.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.